Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria

by Akinobu Nakamura, Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Yoshio Kurihara
Published 2020-01-01

Protective effect of sodium–glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes

by Hideaki Miyoshi, Hiraku Kameda, Kumiko Yamashita, Akinobu Nakamura, Yoshio Kurihara
Published 2019-11-01

Switching to Once-Daily Insulin Degludec/Insulin Aspart from Basal Insulin Improves Postprandial Glycemia in Patients with Type 2 Diabetes Mellitus: Randomized Controlled Trial

by Kyu Yong Cho, Akinobu Nakamura, Chiho Oba-Yamamoto, Kazuhisa Tsuchida, Shingo Yanagiya, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2020-08-01

Effects of switching from a dipeptidyl peptidase-4 inhibitor to luseogliflozin on nocturnal blood pressure in patients with type 2 diabetes: protocol for a multicentre, prospective...

by Kyu Yong Cho, Reina Kameda, Hiroshi Nomoto, Shinichiro Kawata, Kazuno Omori, Jun Takeuchi, So Nagai, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Hideaki Miyoshi
Published 2020-02-01

A Randomized Controlled Trial Comparing the Effects of Sitagliptin and Glimepiride on Endothelial Function and Metabolic Parameters: Sapporo Athero-Incretin Study 1 (SAIS1).

by Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, Koji Oba, Hiroyuki Tsutsui, Atsushi Inoue, Tatsuya Atsumi, Naoki Manda, Yoshio Kurihara, Shin Aoki, SAIS Study Group
Published 2016-01-01

Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea

by Kazuno Omori, Hiroshi Nomoto, Akinobu Nakamura, Takahiro Takase, Kyu Yong Cho, Kota Ono, Naoki Manda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2019-03-01

Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial

by Takahiro Takase, Akinobu Nakamura, Chiho Yamamoto, Hiroshi Nomoto, Aika Miya, Midori Dannoura, Kyu Yong Cho, Yoshio Kurihara, Naoki Manda, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2019-05-01

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

by Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-02-01

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

by Kyu Yong Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Kohei Yamamoto, Hiroshi Nomoto, Hiraku Kameda, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-07-01

Family Support for Medical Nutritional Therapy and Dietary Intake among Japanese with Type 2 Diabetes (JDDM 56)

by Chika Horikawa, Mariko Hatta, Sakiko Yoshizawa Morikawa, Yasunaga Takeda, Mizuki Takeuchi, Kazuya Fujihara, Noriko Kato, Hiroki Yokoyama, Yoshio Kurihara, Koichi Iwasaki, Shiro Tanaka, Hiroshi Maegawa, Hirohito Sone
Published 2020-08-01

A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-I...

by Hiroshi Nomoto, Hideaki Miyoshi, Tomoo Furumoto, Koji Oba, Hiroyuki Tsutsui, Arina Miyoshi, Takuma Kondo, Kenichi Tsuchida, Tatsuya Atsumi, Naoki Manda, Yoshio Kurihara, Shin Aoki, SAIS Study Group
Published 2015-01-01

Comparing Associations of Dietary Energy Density and Energy Intake, Macronutrients with Obesity in Patients with Type 2 Diabetes (JDDM 63)

by Yasunaga Takeda, Kazuya Fujihara, Rina Nedachi, Izumi Ikeda, Sakiko Yoshizawa Morikawa, Mariko Hatta, Chika Horikawa, Mitsutoshi Kato, Noriko Kato, Hiroki Yokoyama, Yoshio Kurihara, Kazuhiro Miyazawa, Hiroshi Maegawa, Hirohito Sone
Published 2021-09-01

The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3)

by Naoyuki Kitao, Hideaki Miyoshi, Tomoo Furumoto, Kota Ono, Hiroshi Nomoto, Aika Miya, Chiho Yamamoto, Atsushi Inoue, Kenichi Tsuchida, Naoki Manda, Yoshio Kurihara, Shin Aoki, Akinobu Nakamura, Tatsuya Atsumi, SAIS Study Group
Published 2017-10-01

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

by Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi, Hideaki Miyoshi
Published 2019-03-01

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

by Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-08-01

Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study

by Kyu Yong Cho, Hiroshi Nomoto, Akinobu Nakamura, Shinichiro Kawata, Hajime Sugawara, Jun Takeuchi, So Nagai, Kazuno Omori, Kazuhisa Tsuchida, Aika Miya, Ikumi Shigesawa, Kenichi Tsuchida, Shingo Yanagiya, Hiraku Kameda, Hiroki Yokoyama, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Naoki Nishimoto, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-08-01